EMA Authorised: Raloxifene Teva (raloxifene hydrochloride) — Teva B.V.

View source ↗

Summary

European Medicines Agency has authorised Raloxifene Teva (raloxifene hydrochloride) for osteoporosis in postmenopausal women.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Raloxifene Teva (raloxifene hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis, Postmenopausal. MAH: Teva B.V.. Decision date: 08/09/2021